Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Serabelisib |
| Trade Name | |
| Synonyms | INK1117|TAK-117|MLN-1117|MLN1117 |
| Drug Descriptions |
Serabelisib (MLN1117) selectively inhibits PI3K alpha kinase, including mutations of PIK3CA, and therefore, targets the PI3K/Akt/mTOR pathway with potentially less toxicity than pan-PI3K inhibitors (PMID: 28490463, PMID: 30168905). |
| DrugClasses | PIK3CA inhibitor 27 |
| CAS Registry Number | 1268454-23-4 |
| NCIT ID | C98844 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Mivavotinib + Serabelisib | Mivavotinib Serabelisib | 0 | 0 |
| Nab-paclitaxel + Serabelisib | Nab-paclitaxel Serabelisib | 0 | 1 |
| Paclitaxel + Sapanisertib + Serabelisib | Paclitaxel Sapanisertib Serabelisib | 0 | 2 |
| Sapanisertib + Serabelisib | Sapanisertib Serabelisib | 0 | 4 |
| Serabelisib | Serabelisib | 4 | 3 |